You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR ATENOLOL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for atenolol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000478 ↗ Asymptomatic Cardiac Ischemia Pilot (ACIP) Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1990-11-01 To assess the feasibility of and test the methodology for a full-scale clinical trial of therapies for asymptomatic cardiac ischemia.
NCT00000513 ↗ Trial of Antihypertensive Intervention Management Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1984-04-01 The objective of the Trial of Antihypertensive Intervention Management (TAIM) was to determine the efficacy of dietary management and/or drug therapy, namely thiazide-like diuretics or a beta-blocker, in the control of mild hypertension. Additionally, the Continuation of the Trial of Antihypertensive Intervention Management (COTAIM) tested the effects of long-term weight reduction, and sodium/potassium changes added to weight reduction, as well as the original drug treatment, on the failure rate of blood pressure control.
NCT00000514 ↗ Systolic Hypertension in the Elderly Program (SHEP) Completed National Institute on Aging (NIA) Phase 3 1984-06-01 The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
NCT00000514 ↗ Systolic Hypertension in the Elderly Program (SHEP) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1984-06-01 The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for atenolol

Condition Name

Condition Name for atenolol
Intervention Trials
Hypertension 40
Essential Hypertension 6
Marfan Syndrome 6
Healthy 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for atenolol
Intervention Trials
Hypertension 44
Essential Hypertension 9
Cardiovascular Diseases 8
Diabetes Mellitus 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for atenolol

Trials by Country

Trials by Country for atenolol
Location Trials
United States 104
Canada 18
China 7
Germany 7
Korea, Republic of 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for atenolol
Location Trials
Florida 8
Minnesota 8
Massachusetts 7
California 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for atenolol

Clinical Trial Phase

Clinical Trial Phase for atenolol
Clinical Trial Phase Trials
Phase 4 48
Phase 3 27
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for atenolol
Clinical Trial Phase Trials
Completed 78
Unknown status 19
Terminated 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for atenolol

Sponsor Name

Sponsor Name for atenolol
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 7
Novartis 4
University of Florida 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for atenolol
Sponsor Trials
Other 123
Industry 50
NIH 11
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.